EUVIMEDEUVIMED entdecken
Vergleichsstudie

A Prospective Comparative Study of High‐Yield Plateletpheresis Using Haemonetics MCS +, Trima Accel, and Spectra Optia Devices in a Resource‐Constrained Setting

Eiman Hussein iD, Azza A Aboul Enein

Journal of Clinical Apheresis · 2025-10 · 40 (5)

DOI: 10.1002/jca.70054 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 05.09.2025. Verfasst von Eiman Hussein und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Chemical Pathology, Division of Transfusion Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Plateletpheresis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a resource‐constrained setting, maximizing plateletpheresis efficiency is critical. We believe leveraging advanced apheresis device software to enhance platelet yield, reduce consumables, and shorten procedure times offers significant advantages. This study compared Haemonetics, Trima, and Optia apheresis devices, analyzing donor and machine parameters. It also assessed how high‐yield collections and recent software updates on Trima and Haemonetics devices impact donor safety. The goal was to find the best practices for optimizing both donor safety and platelet collection. Analyzing 900 procedures (300 per device), Trima and Optia yielded significantly more platelets (9 × 10 11 ) in less time compared to Haemonetics (5.7 × 10 11 ) ( p < 0.05). Trima collected10–12 × 10 11 platelets from significantly more donors with lower pre‐donation counts than Optia ( p < 0.05). Optia led to the fewest adverse events (0.7%). Donor weight was significantly higher for yields > 9 × 10 11 on Optia and Trima ( p < 0.05). Haemonetics' 3.6–3.8 × 10 11 yield group had significantly lower session time, donor weight, and presession platelet counts ( p < 0.05). Software updates (200 sessions/device) significantly boosted Trima's yields to 14.8 × 10 11 while reducing adverse events (1% vs. 2.3% pre‐update). Haemonetics also saw improved yields and fewer adverse events (1% vs. 4.3%), though its overall yield remained lower (6.3 × 10 11 , p < 0.05). Both maintained safe post‐procedure platelet counts (> 130 000/μL). However, Trima's predicted yields for very high collections (> 12 × 10 11 ) significantly differed from lab‐determined yields. Trima and Optia provide better platelet collection efficiency than Haemonetics. Software updates improved both Trima and Haemonetics' performance and safety; however, Trima's high‐yield predictions need refining. Optimal settings, updated software, and careful donor selection are essential for maximizing platelet yield and donor safety in resource‐limited areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlateletpheresisHumansProspective StudiesFemaleMaleAdultMiddle AgedPlatelet CountBlood DonorsSoftwareBlood Platelets

Stichwörter der Autor:innen

HaemoneticsOptiaTrimaadverse eventsdonor blood countskit utilizationplateletpheresis—high yieldssoftware update

Autor:innen und Institutionen

  • Department of Clinical and Chemical Pathology, Division of Transfusion Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.

ORCID-Profile: Eiman Hussein

Zitieren

APA

Hussein, E., & Enein, A. A. A. (2025). A Prospective Comparative Study of High‐Yield Plateletpheresis Using Haemonetics MCS +, Trima Accel, and Spectra Optia Devices in a Resource‐Constrained Setting. Journal of Clinical Apheresis, 40(5). https://doi.org/10.1002/jca.70054

Vancouver

Hussein E, Enein AAA. A Prospective Comparative Study of High‐Yield Plateletpheresis Using Haemonetics MCS +, Trima Accel, and Spectra Optia Devices in a Resource‐Constrained Setting. Journal of Clinical Apheresis. 2025;40(5). doi:10.1002/jca.70054

BibTeX
@article{Hussein2025,
  author = {Hussein, Eiman and Enein, Azza A Aboul},
  title = {A Prospective Comparative Study of High‐Yield Plateletpheresis Using Haemonetics MCS +, Trima Accel, and Spectra Optia Devices in a Resource‐Constrained Setting},
  journal = {Journal of Clinical Apheresis},
  year = {2025},
  volume = {40},
  number = {5},
  doi = {10.1002/jca.70054}
}
Kostenlos starten →